Co-Diagnostics, Inc. (CODX) stock
CODXNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
$0.28−0.01 (-3.78%)
Close on Nov 11, 2026Market cap $1.74MP/E –Yield –
Co-Diagnostics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Co-Diagnostics's EPS for the twelve months ending Sep 30, 2026 was -$20.20. For fiscal 2025 it was -$35.25. The highest annual figure on record is $45.60 in fiscal 2020.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$35.25 | – |
| FY2024 | Dec 31, 2024 | -$37.22 | – |
| FY2023 | Dec 31, 2023 | -$36.00 | – |
| FY2022 | Dec 31, 2022 | -$13.50 | -136.6% |
| FY2021 | Dec 31, 2021 | $36.90 | -19.1% |
| FY2020 | Dec 31, 2020 | $45.60 | – |
| FY2019 | Dec 31, 2019 | -$11.10 | – |
| FY2018 | Dec 31, 2018 | -$15.00 | – |
| FY2017 | Dec 31, 2017 | -$18.90 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$1.01 | – |
| Q2 FY2026 | Jun 30, 2026 | -$1.46 | – |
| Q1 FY2026 | Mar 31, 2026 | -$4.06 | – |
| Q4 FY2025 | Dec 31, 2025 | -$13.67 | – |
| Q3 FY2025 | Sep 30, 2025 | -$4.66 | – |
| Q2 FY2025 | Jun 30, 2025 | -$7.00 | – |
| Q1 FY2025 | Mar 31, 2025 | -$7.05 | – |
| Q4 FY2024 | Dec 31, 2024 | -$10.72 | – |
| Q3 FY2024 | Sep 30, 2024 | -$9.60 | – |
| Q2 FY2024 | Jun 30, 2024 | -$7.50 | – |
| Q1 FY2024 | Mar 31, 2024 | -$9.30 | – |
| Q4 FY2023 | Dec 31, 2023 | -$14.94 | – |
| Q3 FY2023 | Sep 30, 2023 | -$6.00 | – |
| Q2 FY2023 | Jun 30, 2023 | -$9.30 | -191.2% |
| Q1 FY2023 | Mar 31, 2023 | -$6.00 | -180.0% |
| Q3 FY2022 | Sep 30, 2022 | -$1.20 | -110.5% |
| Q2 FY2022 | Jun 30, 2022 | -$2.40 | -124.2% |
| Q1 FY2022 | Mar 31, 2022 | $10.20 | +30.8% |
| Q4 FY2021 | Dec 31, 2021 | $7.50 | -43.1% |
| Q3 FY2021 | Sep 30, 2021 | $11.40 | -28.3% |
| Q2 FY2021 | Jun 30, 2021 | $9.90 | -35.3% |
| Q1 FY2021 | Mar 31, 2021 | $7.80 | – |
| Q4 FY2020 | Dec 31, 2020 | $13.19 | – |
| Q3 FY2020 | Sep 30, 2020 | $15.90 | – |
| Q2 FY2020 | Jun 30, 2020 | $15.30 | – |
| Q1 FY2020 | Mar 31, 2020 | -$1.50 | – |
| Q4 FY2019 | Dec 31, 2019 | -$3.14 | – |
| Q3 FY2019 | Sep 30, 2019 | -$3.00 | – |
| Q2 FY2019 | Jun 30, 2019 | -$2.40 | – |
| Q1 FY2019 | Mar 31, 2019 | -$2.70 | – |
| Q4 FY2018 | Dec 31, 2018 | -$4.53 | – |
| Q3 FY2018 | Sep 30, 2018 | -$3.90 | -100.0% |
| Q2 FY2018 | Jun 30, 2018 | -$3.30 | – |
| Q1 FY2018 | Mar 31, 2018 | -$3.30 | – |
| Q3 FY2017 | Sep 30, 2017 | -$9.90 | – |
| Q2 FY2017 | Jun 30, 2017 | $105896880.00 | – |
| Q4 FY2016 | Dec 31, 2016 | -$1.59 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?